<DOC>
	<DOCNO>NCT00910780</DOCNO>
	<brief_summary>This project aim identify whether therapeutic substitution aripiprazole risperidone olanzapine , combine standard nutrition intervention , impact metabolic change associate antipsychotic treatment child adolescent .</brief_summary>
	<brief_title>Metabolic Effects Antipsychotic Substitution Children</brief_title>
	<detailed_description />
	<mesh_term>Risperidone</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Age 618 year ( point study participation BMI &gt; 85th percentile One DSMIV diagnosis , include disruptive behavior disorder ( attention deficit disorder , conduct disorder , oppositional defiant disorder disruptive behavior disorder otherwise specify ) , affective disorder ( bipolar affective disorder , major depressive disorder mood disorder otherwise specify ) , anxiety disorder ( generalize anxiety disorder , obsessive compulsive disorder , separation anxiety , social specific phobia ) well disorder , include autism spectrum disorder ( autistic disorder , Asperger 's Syndrome pervasive developmental disorder otherwise specify ) , psychotic disorder ( schizophreniform disorder , schizophrenia psychotic disorder otherwise specify ) movement disorder ( tic disorder , Tourette 's Syndrome ) At least 12 week treatment approximately 12 month treatment risperidone olanzapine immediately prior study enrollment ( assume initial phase prior treatment involve dose titration ; clinically minor dose deviation change dose missed dos evaluate inclusion PI individual basis ) No clinically significant change permit medication ( e.g. , stimulant ) 1 month prior Baseline Evaluations ( inclusion determine evaluation individual basis PI ) Clinically significant weight gain initial course antipsychotic treatment ; nonMEAC participant , define &gt; 10 % increase baseline weight prior treatment treatment last approximately 512 month define &gt; 7 % increase baseline weight prior treatment treatment last approximately 34 month ( base totality information primary care provider , school home ) ; prior MEAC participant , clinically significant weight gain define &gt; 7 % increase baseline weight course 3 month MEAC study and/or &gt; 10 % increase total body fat measure DEXA MEAC study Score &gt; 18 irritability subscale Aberrant Behavior Checklist prior initiate antipsychotic treatment : MEAC participant automatically meet criterion base similar inclusion criterion MEAC ; nonMEAC participant , ABC questionnaire administer parent one collateral source ( teacher , social worker alternate caregiver ) study staff retrospectively gather information symptom irritability aggression prior initiation antipsychotic treatment . NonMEAC participant retrospective , consensus ( i.e. , clinician evaluation available source ABC data ) ABC irritability subscale score &gt; 18 proximity ( e.g. , within 3 month ) initiation treatment include ( base combine evaluation totality available corroborative resource ) , viii ) Clinically significant improvement psychiatric symptom initial course antipsychotic base &gt; 30 % decrease ABC irritability score baseline endpoint MEAC study retrospective consensus 30 % decrease ABC prior course treatment OR CGII score 2 good psychiatric symptom experience least 1 month prior enrollment measure CGIS score 3 less ( mildly ill ) . Active suicidality The presence serious medical disorder condition may , judgment PI , confound assessment relevant biologic measure diagnosis , include : clinically significant organ system dysfunction ; significant endocrine disease , include diabetes mellitus ; coagulopathy ; significant anemia ; significant acute infection ; pregnancy Participants take within last 3 month glucose lower agent , lipid lowering agent , exogenous testosterone , recombinant human growth hormone , endocrine agent might confound substrate metabolism , oral glucocorticoid ( glucocorticoid nasal spray inhaler permit ) , sedate antihistamine ( nonsedating antihistamine like Claritin ( loratadine ) Zyrtec ( cetirizine ) permit ) , non serotonin selective reuptake inhibitor antidepressant mood stabilize agent ( exposure SSRI 's , stimulant , clonidine guanfacine permit ) IQ &lt; 70 ( base school record and/or evaluation clinician ) Current substance abuse ; vi ) past history , current dyskinesia Stimulant dosage higher approximately 2 mg/kg/day methylphenidate equivalent dose nonmethylphenidate stimulant Participants baseline elevate total cholesterol low density lipoprotein cholesterol ( &gt; 95th percentile age gender ) exclude base recent American Academy Pediatric recommendation treat level dyslipidemia pharmacotherapy , ( 63 ) unless document achieve &gt; 95th percentile dyslipidemia antipsychotic treatment baseline ( e.g. , MEAC recruit ) give clinical equipoise around whether plan intervention could lower lipid back threshold allow avoid risk lipid lower drug Baseline fast triglyceride &gt; 400 mg/dl</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>